Trude Eid Robsahm joined the Cancer Registry in 1995 and has been working as a researcher and, since 2004, as the head of the Section for Epidemiology and Prevention. In 2004, Trude completed her doctoral degree at the Faculty of Medicine (UiO) with a dissertation titled "The influence of etiological factors in sensitive periods of life on cutaneous malignant melanoma, breast-, colon- and prostate cancer: an epidemiologic study focusing mainly on residential history in Norway." Her research focuses on the significance of modifiable lifestyle factors (such as UV exposure, physical activity, obesity, vitamin D) for both cancer incidence and survival. She teaches register-based research and cancer epidemiology at colleges and universities, mentors/several Ph.D. candidates and postdoctoral fellows, and serves on several external expert councils and evaluation committees.
Trude Eid Robsahm is a researcher and section leader for etiology and prevention.
She has a particular interest in the significance of modifiable lifestyle factors for both cancer risk and survival.
She is the Cancer Registry's expert on skin cancer, with a specific focus on melanoma. UV radiation from the sun is the most important risk factor, but she also investigates whether other factors such as lifestyle and the use of various medications affect the incidence and survival. Using histopathological data from the Melanoma Registry, she studies gender differences, challenges in diagnostics, and other factors for more targeted prevention.
UV radiation is also a significant source of vitamin D, and in several prognostic studies, she has examined the possible inhibitory role of vitamin D in cancer development.
In several projects, she also studies how physical activity/fitness affects both cancer incidence and prognosis.
She teaches students in register-based research and cancer epidemiology at colleges and universities. She mentors and has mentored several Ph.D. candidates and postdoctoral fellows, and she is involved in several external expert councils and evaluation committees.
Robsahm has a master's degree in sports science/physiology (NTNU, 1993) and has been employed at the Cancer Registry since 1995.
She completed her doctoral degree in 2004 at the Faculty of Medicine (UiO) with a dissertation titled "The influence of etiological factors in sensitive periods of life on cutaneous malignant melanoma, breast-, colon- and prostate cancer: an epidemiologic study focusing mainly on residential history in Norway."
Since then, she has worked as a researcher in the Research Department.
Publikasjoner:
Nordsletten M, Saeed U, Myklebust TÅ, Robsahm TE, Møller B, Skålhegg BS, Mala T, Yaqub S. Body mass index and its association with 22 cancer types: a Norwegian cohort study of 481 202 cancer cases. Acta Oncol. 2023 Oct;62(10):1273-1278. doi: 10.1080/0284186X.2023.2258443. Epub 2023 Sep 15. PMID: 37713274.
Robsahm TE, Falk RS, Eide NA. Additional malignancies and mortality in uveal melanoma: A 20-year follow-up of a Norwegian patient cohort. Acta Ophthalmol. 2023 Sep;101(6):696-704. doi: 10.1111/aos.15659. Epub 2023 Mar 16. PMID: 36924309.
Ghiasvand R, Berge LAM, Andreassen BK, Green AC, Al Rahmoun M, Fournier A, Kvaskoff M, Veierød MB, Robsahm TE. Statin use and risk of cutaneous melanoma: a nationwide nested case-control study. Br J Dermatol. 2023 May 24;188(6):805-807. doi: 10.1093/bjd/ljad057. PMID: 36866569.
Perrier F, Robsahm TE, Ghiasvand R, Borch KB, Braaten T, Weiderpass E, Rueegg CS, Green AC, Veierød MB. No association between physical activity and primary melanoma thickness in a cohort of Norwegian women. Br J Dermatol. 2023 Apr 20;188(5):670-690. doi: 10.1093/bjd/ljac136. PMID: 36718120.
Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H. Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway. Acta Oncol. 2023 Jan;62(1):8-14. doi: 10.1080/0284186X.2023.2175331. Epub 2023 Feb 10. PMID: 36762472; PMCID: PMC10301241.
Robsahm TE, Tretli S, Torjesen PA, Babigumira R, Schwartz GG. Serum 25-hydroxyvitamin D levels predict cancer survival: a prospective cohort with measurements prior to and at the time of cancer diagnosis. Clin Epidemiol. 2019 Aug 8;11:695-705. doi: 10.2147/CLEP.S207230. PMID: 31496824; PMCID: PMC6690592.
Robsahm TE, Heir T, Sandvik L, Prestgaard E, Tretli S, Erikssen JE, Falk RS. Changes in midlife fitness, body mass index, and smoking influence cancer incidence and mortality: A prospective cohort study in men. Cancer Med. 2019 Aug;8(10):4875-4882. doi: 10.1002/cam4.2383. Epub 2019 Jul 4. PMID: 31270954; PMCID: PMC6712445.
Media:
Kreftregisteret: 13.000 krefttilfeller kunne vært unngått - Forskning.no 2023
Hver dag får 6 nordmenn føflekkreft - NRK 2023
Nordmenn kunne sluppet flere typer kreft - Klar tale 2023
Podcast: Ganske aktuelt #10 Kreft, årsaker, solkrem og forebyggende - 2023
